-

Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies and life science solutions, today announced the launch of Able AI, a first-of-its-kind artificial intelligence tool that is now available on ptglab.com.

Use Able AI now for tailored product recommendations and experimental design support at ptglab.com/able

Share

Finding the most suitable antibodies from the vast pool of potential products is a challenge. Able helps scientists pinpoint the right antibody based on their research needs, while also providing all relevant information and associated scientific knowledge. In addition, it offers detailed guidance on product specific experimental procedures, significantly reducing the time spent on planning and product selection.

This release follows Proteintech’s successful introduction of 3D Epitope Mapping earlier this year, which advanced researchers’ ability to visualize antibody binding sites through experimental and AI-powered modelling. This capability reduces guesswork and trial-and-error, enabling scientists to better design experiments and develop products with greater precision.

Able represents the next phase in our mission to empower scientists,” said Dr. Jason Li, CEO of Proteintech. “Building on the success of our 3D Epitope Mapping platform, Able delivers tailored product recommendations and experimental design support, allowing researchers to focus more on their cutting-edge discoveries. Proteintech strives to push boundaries in the reagent world for better science and better service for every customer.

Able is available immediately and free to use at ptglab.com or directly at www.ptglab.com/Able.

About Proteintech

Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering two-thirds of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 300,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.

For more information, visit ptglab.com.

Contacts

Katie Bellows
katie@ptglab.com
ph: 312-455-8498

More News From Proteintech Group Inc.

Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. The 3D Epitope Mappi...

Proteintech Genomics Launches the MultiPro® Human Discovery Panel: A New Frontier in Single-Cell Multiomics

SAN DIEGO--(BUSINESS WIRE)--Proteintech Genomics, a leader in antibody-based multiplexed solutions for single-cell multiomics, today announced the launch of its MultiPro® Human Discovery Panel, a groundbreaking antibody panel designed to transform single-cell multiomics research. This new panel enables scientists to profile 325 proteins alongside whole transcriptome analysis within single cells, offering a multiomic approach that delivers deeper insights into cellular functions. The MultiPro® H...

Proteintech Germany triples its space with a new office and laboratory

MARTINSRIED/PLANEGG, Germany--(BUSINESS WIRE)--Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space. In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-ba...
Back to Newsroom